Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC9A1 | P19634 | 7/20 | 0.48 |
| ▸ | GRM2 | Q14416 | 2/20 | 0.48 |
| ▸ | PTK2 | Q05397 | 4/20 | 0.46 |
| ▸ | LMNA | P02545 | 2/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.45 |
| ▸ | TP53 | P04637 | 1/20 | 0.45 |
| ▸ | HPGD | P15428 | 1/20 | 0.45 |
| ▸ | TSHR | P16473 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.45 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.45 |
| ▸ | KCNMA1 | Q12791 | 1/20 | 0.44 |
| ▸ | GAA | P10253 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5861811 | 0.83 | SLC9A1 (0.65) | SLC9A1HPGDTSHRKMT2AGAA | |
| SCHEMBL5859932 | 0.83 | SLC9A1 (0.51) | SLC9A1GRM2PTK2LMNAALDH1A1 | |
| SCHEMBL5859138 | 0.82 | TSHR (0.65) | SLC9A1GRM2LMNAALDH1A1TP53 | |
| SCHEMBL5858823 | 0.82 | POLB (0.48) | SLC9A1GRM2PTK2LMNAALDH1A1 | |
| SCHEMBL5858757 | 0.82 | SLC9A1 (0.48) | SLC9A1GRM2PTK2LMNAALDH1A1 | |
| Iodide SCHEMBL5861908 | 0.81 | TSHR (0.47) | SLC9A1GRM2PTK2LMNAALDH1A1 | |
| Hydrochloric Acid SCHEMBL5859906 | 0.81 | POLB (0.47) | SLC9A1GRM2LMNAALDH1A1TP53 | |
| Trimethylammonium SCHEMBL5861905 | 0.81 | SLC9A1 (0.47) | SLC9A1GRM2PTK2LMNAALDH1A1 | |
| SCHEMBL19257743 | 0.80 | SLC9A1 (0.67) | SLC9A1GRM2LMNAALDH1A1TSHR | |
| SCHEMBL5859675 | 0.80 | TSHR (0.52) | SLC9A1GRM2PTK2LMNAALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7030140-B2 | Substituted benzimidazole antiviral agents | BRISTOL-MYERS SQUIBB COMPANY (US) | 2006-04-18 | — | — | US | disclosed |
| US-6908936-B2 | Substituted benzimidazole antiviral agents | BRISTOL-MYERS SQUIBB COMPANY (US) | 2005-06-21 | — | — | US | disclosed |
| US-20050038085-A1 | Substituted benzimidazole antiviral agents | YU KUO-LONG (US) | 2005-02-17 | — | — | US | disclosed |
| US-20030139450-A1 | Substituted benzimidazole antiviral agents | YU KUO-LONG (US) | 2003-07-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050038085-A1 | Substituted benzimidazole antiviral agents | MAVS, ZC3HAV1, ZC3HAV1L | SLC9A1 3922/4885GRM2 4631/4885PTK2 4866/4885 |
| US-20030139450-A1 | Substituted benzimidazole antiviral agents | MAVS, ZC3HAV1, ZC3HAV1L | SLC9A1 3922/4885GRM2 4631/4885PTK2 4866/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.